Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic

TÖRÜNER M., Kalkan I. H., Akyuz F., Tezel A., ÇELİK A. F.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.6, pp.488-492, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.5152/tjg.2021.280721
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.488-492
  • Keywords: Inflammatory bowel diseases, Crohn's disease, ulcerative colitis, COVID-19 pandemic, IMMUNE-RESPONSE, OPPORTUNISTIC INFECTIONS, VACCINE, THERAPY, CROHNS, RISK
  • Istanbul University Affiliated: No


The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic.